News and Trends 8 Jun 2023
Minoryx can start phase 3 trial for cerebral adrenoleukodystrophy patients
Spanish-headquartered Minoryx Therapeutics says the U.S. Food and Drug Administration (FDA) has approved its phase 3 clinical trial (CALYX) of lead candidate leriglitazone, to treat adult male X-linked adrenoleukodystrophy (X-ALD)…